Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Compounded semaglutide is not Ozempic. Storage rules come from the 503A pharmacy that prepared the medication, not from Novo Nordisk
- Beyond-use dates follow USP 797 standards for compounded sterile preparations and are typically shorter than brand product shelf life
- Room-temperature allowances for compounded semaglutide vary widely by formulation, often shorter than 56 days, sometimes only hours
- Compounded products are not FDA-approved; they are legal under section 503A when prescribed for an individual patient
- Always follow the storage instructions from your specific dispensing pharmacy
Direct answer
The room-temperature window for compounded semaglutide is set by the 503A compounding pharmacy that prepared your specific medication. The window depends on the formulation, the packaging, the preservative system, and the pharmacy's stability data. Typical refrigerated beyond-use dates range from 28 to 90 days; room-temperature allowances are usually shorter. Compounded semaglutide does not follow the 56-day room-temperature rule that applies to brand Ozempic. Follow the label from your dispensing pharmacy.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Table of contents
- Why compounded semaglutide storage is different from Ozempic
- What 503A compounding means
- USP 797 standards and beyond-use dating
- Typical compounded semaglutide formulations
- How to read your pharmacy label
- What to do if storage instructions are unclear
- What changes if the formulation includes a preservative
- The regulatory distinction: not FDA-approved
- Heat exposure and what it does to compounded semaglutide
- Freezing and the absolute discard rule
- Decision framework for compounded semaglutide
- FAQ
- Sources
Why compounded semaglutide storage is different from Ozempic
Compounded semaglutide and brand Ozempic share an active ingredient (semaglutide), but they are operationally and regulatorily different products.
Ozempic is manufactured by Novo Nordisk under FDA oversight. The product is identical batch to batch. The pen, concentration, preservative system, and stability profile are tested extensively before approval and monitored continuously after. Novo Nordisk's 56-day room-temperature window reflects stability testing the company submitted for FDA review.
Compounded semaglutide is prepared by a 503A pharmacy filling a prescription for an individual patient. The pharmacy sources semaglutide active ingredient (often as a powder or concentrated solution), combines it with excipients of the pharmacy's choice, adds a preservative system if needed, and packages the result in vials, syringes, or other formats. Each pharmacy's product is different from another pharmacy's, and the same pharmacy's product may vary by batch depending on sourcing and preparation.
The result: storage rules for compounded semaglutide cannot be extrapolated from Ozempic. Each compounded product follows the specific rules set by the pharmacy that prepared it.
What 503A compounding means
Section 503A of the Federal Food, Drug, and Cosmetic Act governs pharmacies that prepare compounded medications for individual patients. A 503A pharmacy operates under a state license and prepares medications based on prescriptions from licensed prescribers.
Key features of 503A:
- Each compounded medication is prepared for a specific patient with a valid prescription
- The pharmacy follows USP 797 standards for sterile compounding
- The pharmacy holds a state license, not an FDA manufacturing approval
- Compounded products are not FDA-approved
- The pharmacy assigns beyond-use dates based on USP defaults or its own stability data
503A is the legal pathway by which compounded semaglutide reaches patients in the U.S. The framework permits compounding without FDA new-drug approval, which makes the products legally available but not FDA-vetted.
503A is distinct from 503B, which is the framework for outsourcing facilities that prepare medications in larger batches without individual prescriptions. 503B facilities follow stricter manufacturing requirements and are FDA-registered. Most compounded semaglutide is dispensed under 503A, not 503B.
The 503A designation does not lower storage requirements. The pharmacy must still follow USP 797 and assign appropriate beyond-use dates.
USP 797 standards and beyond-use dating
USP 797 is the chapter of the United States Pharmacopeia that governs pharmaceutical compounding of sterile preparations. It defines requirements for cleanroom standards, personnel training, environmental monitoring, and beyond-use dating (BUD) for compounded medications.
USP 797 BUDs depend on:
- Compounding risk category (low, medium, high) based on complexity
- Whether sterility testing is performed
- Storage temperature (refrigerated, room temperature, frozen)
- Specific stability data, if the pharmacy has it
Default USP 797 BUDs for sterile compounded preparations without specific stability data:
| Risk category | Refrigerated BUD | Room temperature BUD |
|---|---|---|
| Category 1 (simple compounding) | 14 days | 12 hours |
| Category 2 (more complex) | 45 days refrigerated, 90 days frozen | 4 days |
| Category 3 (extended BUDs) | Up to 60 days refrigerated, 180 days frozen | 10 days, with sterility testing |
If a pharmacy has specific stability data for its semaglutide formulation, it may assign longer BUDs supported by that data. If not, USP defaults apply.
The implication: compounded semaglutide BUDs vary widely. A pharmacy with category 2 sterile compounding and no specific stability data may assign a refrigerated BUD of 45 days. A pharmacy with specific stability data may assign 60 to 90 days. A pharmacy operating under category 1 with no specific data may assign only 14 days refrigerated and 12 hours at room temperature.
Typical compounded semaglutide formulations
Compounded semaglutide reaches patients in several common formats:
Multi-dose vial with preservative. A vial containing multiple doses with a preservative (often benzyl alcohol or m-cresol) added to allow repeated needle access without contamination. Typical refrigerated BUDs are 28 to 90 days; room-temperature BUDs are 4 to 14 days depending on category and stability data.
Preservative-free vial. Single-use or short multi-dose without added preservative. Shorter BUDs because of higher contamination risk after needle access. Typical refrigerated BUDs are 14 to 28 days; room-temperature BUDs are 12 hours to 4 days.
Prefilled syringe. Single dose drawn into a sterile syringe by the pharmacy. BUDs vary; typically 28 to 60 days refrigerated.
Compounded combinations. Some pharmacies offer semaglutide combined with other ingredients like B12 or vitamin complexes. These combinations add complexity to stability and typically have shorter BUDs than semaglutide alone.
The specific format and BUD for your medication are on the label. Different pharmacies use different formats, even for the same active ingredient at the same dose.
How to read your pharmacy label
The label on compounded semaglutide should include:
- Patient name and prescriber
- Medication name (semaglutide) and concentration
- Total volume and number of doses
- Storage instructions (typically refrigerate at 2-8 degrees Celsius)
- Beyond-use date
- Lot number and pharmacy contact information
- Auxiliary labels for special handling (light protection, etc.)
Key questions to answer from your label:
- What is the beyond-use date? Use this as the discard deadline.
- What is the room-temperature allowance, if specified? Some pharmacies state this; others say "refrigerate" without specifying a room-temperature window.
- How should I store the vial after each use? Typically return to fridge promptly.
- What does the medication look like when stable? Most labels do not specify, but the visual should be clear and free of particles.
If the label does not specify a room-temperature allowance, the safe assumption is to refrigerate continuously, taking the medication out only for the brief moment of drawing and injecting a dose.
What to do if storage instructions are unclear
Contact the dispensing pharmacy. They can provide:
- The specific beyond-use date for your medication
- Any room-temperature allowance for transit or brief exposure
- The temperature ceiling above which the medication should be discarded
- Visual inspection criteria for stability
- Replacement procedures if you suspect a storage failure
Most 503A pharmacies dispensing compounded GLP-1 medications have call centers or chat support for storage and use questions. Their answers take precedence over any general guidance you find online, including this article.
Do not extrapolate from Ozempic. The 56-day room-temperature rule does not apply to compounded semaglutide. Applying brand rules to compounded product may produce either premature discard or unsafe extended use, depending on the specific formulation.
What changes if the formulation includes a preservative
Preservatives extend the safe in-use window for multi-dose vials by preventing bacterial growth after needle access. Common preservatives in compounded semaglutide:
- Benzyl alcohol
- m-Cresol
- Phenol
Preservative-containing formulations typically have longer in-use windows than preservative-free formulations because the preservative prevents microbial contamination after the vial is accessed.
Preservative-free formulations have shorter beyond-use dates because each needle access introduces potential contamination that the preservative would otherwise prevent. Some preservative-free preparations are designed for single use, with the entire vial used in one preparation and any remaining medication discarded.
The pharmacy label should indicate whether the medication contains a preservative. If unclear, contact the pharmacy.
For storage planning, the implication: preservative-free compounded semaglutide is less forgiving of cold-chain breaks and brief room-temperature exposures than preservative-containing formulations. Refrigerate consistently and use within the labeled window.
The regulatory distinction: not FDA-approved
Compounded semaglutide is not FDA-approved. This is a meaningful regulatory distinction.
FDA-approved medications like Ozempic and Wegovy have undergone:
- Preclinical safety testing
- Phase 1, 2, and 3 clinical trials
- FDA review of efficacy and safety data
- Manufacturing facility inspections
- Ongoing post-marketing surveillance
- Standardized labeling with stability data
Compounded medications are subject to:
- USP 797 standards for sterile compounding
- State pharmacy board oversight
- The 503A statutory framework
Compounded medications are not subject to:
- FDA new-drug approval
- FDA review of efficacy data
- Standardized stability testing across manufacturers
- Batch-to-batch consistency at the population level
This is not necessarily a safety statement. Reputable 503A pharmacies prepare compounded semaglutide carefully and many patients have safe, effective experiences. But it is a regulatory statement: compounded products do not equal FDA-approved products in oversight or testing.
Storage rules reflect this. Compounded products carry shorter beyond-use dates not because they fail faster but because the pharmacy commits only to durations supported by its specific data, which is typically less extensive than what large pharmaceutical manufacturers generate.
Heat exposure and what it does to compounded semaglutide
Like all semaglutide, compounded semaglutide is a peptide that degrades faster with heat. Above the labeled temperature ceiling (typically 86 degrees Fahrenheit or whatever the pharmacy specifies), degradation accelerates and potency may be reduced.
The damage mechanisms are the same as for brand semaglutide:
- Deamidation of amino acid residues
- Oxidation of methionine and tryptophan
- Aggregation of peptide molecules
- Hydrolysis at extreme conditions
The differences for compounded product:
- The specific excipient and preservative system may affect heat sensitivity
- The pharmacy has not necessarily tested heat stability extensively
- Visual inspection criteria may be less specific than for brand product
If your compounded semaglutide has been exposed to heat above the labeled ceiling, contact the pharmacy. They can advise on whether the medication should be discarded based on the specific exposure and their stability data.
Freezing and the absolute discard rule
Freezing typically damages compounded semaglutide as it does brand semaglutide. Ice crystals disrupt peptide structure; preservative can precipitate; vial seals can be compromised.
Most pharmacy labels for compounded semaglutide specify do not freeze. If a vial has been frozen, even briefly, the conservative answer is to discard.
Some pharmacies use frozen storage as part of extended beyond-use dating. In these cases, the pharmacy ships frozen medication and the patient thaws and refrigerates on arrival. Once thawed for use, freezing again is generally not permitted. Follow the specific instructions from your pharmacy.
If you are uncertain about freezing exposure, contact the pharmacy. Visual inspection cannot reliably confirm or rule out freezing damage.
Decision framework for compounded semaglutide
For a compounded semaglutide medication you are evaluating:
1. Has the beyond-use date passed? If yes, discard. If no, continue.
2. Has the medication been frozen (when not intended for frozen storage)? If yes or uncertain, contact pharmacy or discard.
3. Has the medication exceeded the labeled temperature ceiling? If yes for sustained periods, discard. If brief and mild, contact pharmacy.
4. Is the medication clear and free of particles? If no, discard.
5. Is the pharmacy reachable for questions? If unclear about any of the above, call them before injecting.
The cleanest habit for compounded semaglutide: refrigerate immediately on receipt, follow the pharmacy label exactly, contact the pharmacy with any uncertainty rather than extrapolating from brand product rules.
FAQ
How long can compounded semaglutide be out of the fridge? Follow the dispensing pharmacy's label. Room-temperature windows for compounded products are typically shorter than for brand Ozempic.
Is compounded semaglutide the same as Ozempic? No. Same active ingredient, different product, different rules.
What is a beyond-use date? The pharmacy-assigned discard date for compounded medications under USP 797 standards.
Why is compounded semaglutide's window shorter than Ozempic's? Less stability testing supports compounded products; pharmacies commit only to BUDs their data supports.
Can I apply Ozempic rules to compounded? No. Use the pharmacy's specific instructions.
What if my label is unclear? Contact the dispensing pharmacy directly.
What does 503A mean? The statutory framework for pharmacies preparing compounded medications for individual patients with prescriptions.
Is compounded semaglutide FDA-approved? No. It is legal under section 503A but not FDA-approved.
Sources
- United States Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding Sterile Preparations, 2023 revision.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy Compounding, current as of 2024.
- U.S. Food and Drug Administration. FDA's Human Drug Compounding Progress Report, 2023.
- Novo Nordisk Inc. Ozempic (semaglutide) injection prescribing information, revised 2024 (for comparison).
- Novo Nordisk Inc. Wegovy (semaglutide) injection prescribing information, revised 2024 (for comparison).
- National Association of Boards of Pharmacy. State pharmacy compounding regulations summary, 2024.
- Manning MC, Patel K, Borchardt RT. Stability of Protein Pharmaceuticals. Pharmaceutical Research 2010;27(4):544-575.
- U.S. Food and Drug Administration. Compounded Drug Products that Are Essentially Copies of Approved Drug Products, Guidance for Industry, 2023.
- American Pharmacists Association. Compounding practice standards and beyond-use dating, 2024.
- International Conference on Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products, 2003.
- FDA Drug Safety and Availability. FDA's concerns with unapproved GLP-1 drugs used for weight loss, 2024 communication.
Footer disclaimers
Platform Disclaimer. FormBlends provides telehealth services and educational content. Storage rules for compounded semaglutide are set by the dispensing 503A pharmacy, not by FormBlends. Follow the storage instructions on the medication label from your pharmacy.
Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by state-licensed 503A pharmacies under USP 797 standards and is legal when prescribed for an individual patient. Compounded products are not chemically identical to Ozempic or Wegovy in their final dosage forms and do not follow the same storage labeling.
Results Disclaimer. Storage outside the labeled range can reduce medication potency, which may affect appetite control, weight outcomes, and glycemic effects. Compounded products have less stability data than FDA-approved medications, so the clinical impact of storage failures may be harder to predict.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. USP (United States Pharmacopeia) is a registered trademark of the United States Pharmacopeial Convention. FormBlends has no commercial affiliation with these organizations.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →